{"schema_version":"secwatch.filing_event.v1","accession":"0001651308-24-000110","form_type":"8-K","ticker":"ONC","cik":"0001651308","company_name":"BeOne Medicines Ltd.","filed_at":"2024-08-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.966546+00:00","generated_at":"2026-05-31T06:59:49.020254+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"BeiGene reports H1 2024 R&D expenses by product; total R&D up 10% YoY to $915M","bullets":["Zanubrutinib R&D expense $62.9M in H1 2024, down 22% from $81.1M in H1 2023.","Tislelizumab R&D expense $34.5M in H1 2024, down 27% from $47.0M in H1 2023.","Bcl-2 (BGB-11417) R&D expense $38.6M in H1 2024, up 120% from $17.5M in H1 2023.","Total R&D expense $915.1M in H1 2024 vs $831.3M in H1 2023, +10.1% YoY.","R&D collaboration projects $82.5M in H1 2024, up from $23.3M in H1 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001651308-24-000110","json":"https://secwatch.observer/filing/0001651308-24-000110.json","markdown":"https://secwatch.observer/filing/0001651308-24-000110.md","text":"https://secwatch.observer/filing/0001651308-24-000110.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1651308/000165130824000110/0001651308-24-000110-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1651308/000165130824000110/bgne-20240829.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T06:59:49.020254+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}